When Göran Gustafsson Prize, one of Sweden's most sought-after prizes for younger researchers, is awarded, two of the prize winners are from Lund University. The prize in physics goes to Anders Johansen, Lund University, "for his pioneering research on the formation and development of planets near young stars". The award in medicine goes to Kristian Pietras, Lund University, "for his breakthrough analysis of the cancer-associated microenvironment and its role in tumor development".
A research team from the Division of Computational Biology at Lund University and Bionamic, were recently announced as winners of the “NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge” arranged by Food and Drug Administration (FDA) and National Cancer Institute (NCI). The challenge is a part of President Barack Obama’s Precision Medicine Initiative from 2015.
Mislabeled biological samples significantly contribute to non-reproducibility and erroneous decisions in omics data (RNA and protein measurements) driven research, but is a source of error often ignored. The goal of this challenge was to develop algorithms to detect and correct this type of errors. The organizers had deliberately introduced sample mislabeling (accidental swapping of patient samples) or data mislabeling (accidental swapping of patient omics data) at rates and in patterns previously observed in various data sets in these types of datasets.
The algorithm developed by Anders Carlsson (Bionamic), Patrik Edén, Mattias Ohlsson, Björn Linse, and Carsten Peterson (LU) identified and corrected 100% of errors without introducing new ones and outperformed academic and commercial research groups from USA, Europe and Asia.
The method, built using various Artificial Intelligence (AI) components, will be presented at a conference in Washington D.C in May, and is due to be published together with the organizers in Nature Medicine.
Professor Carsten Peterson: “This is another example where AI technologies enter the scene with its power. However, to reach the final percentage profound application knowledge is needed.”
Anders Carlsson,PhD, founder of Bionamic, the success was due to “the broad range of world-class knowledge in our team, and our unique ability to combine them.
References: Nature Medicine 24, 1301–1302 (2018) for background;
https://precision.fda.gov/challenges/5/view/resultsfor the results
"Wrong" type of connective tissue cells gives worse prognosis for breast cancer
In some cancers, connective tissue is formed around and within the tumor. A hypothesis, which has not been proven so far, is that there are several different types of connective tissue cells that have different functions and which can thus affect tumor development in different ways. But now a research group at Lund University has identified three different types of connective tissue cells, and in breast cancer patients studies found that two of these are linked to a worse forecast.
Read the full story here
Chasing this years Nobel Prize laureate
Professor Carl Borrebaeck, held an inspiring talk at TEDxLund, www.tedxlund.se, hosted by Medicon Village and MAX IV.
The theme of TEDxLund "Prima Materia." The event featured speakers, presenting in front of an audience, and was recorded in its entirety and then streamed to another 100 audience members at Medicon Village (Auditorium). In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TED Talks video and live speakers combine to spark deep discussion and connection.
See the TEDx talk here.
Multidisciplinarily research to find new treatments for cancer
Within CREATE Health we use a multidisciplinary approach to defeat cancer. We utilize knowledge from research areas such as cancer stem cells, immuno-oncology, tumor micro-environment, and the psychological effect on cancer. This approach has been very rewarding, and the outcome was presented in DN today.
Professor Thoas Fioretos - Wallenberg Clinical Fellow
Professor Thoas Fioretos, one of CREATE healths principal investigators is one of 4 active chief physicians who was awarded this years Wallenbergs Clinical fellow grant. As a Wallenberg Clinical Scholar, he will develop new methods to improve diagnostics, treatment selection, and follow-up of patients diagnosed with leukemia. The project will also provide important insights into why leukemia develops. The grant is from Wallenberg is on SEK 15 million over a 5 year period, with the possibility for an extension for another 5 years.
New treatment for aggressive breast cancer
Professor Kristian Pietras publish new study in Nature Medicine.
The researcher team lead by Professor Kristin Pietras has developed a new drug that transforms aggressive breast cancer so that it becomes responsive to standard hormone therapy. Approximately 10–15 per cent of breast cancer cases do not respond to treatment with hormone therapy, which means that they are more aggressive and often recur. An international research team led by researchers at Lund University in Sweden has uncovered a way to treat these aggressive tumours through manipulation of the connective tissue cells of the tumour.
Read more at link
Or Listen to Kristian Pietras here
At the service of cancer patients
A collaboration partner to CREATE Health Lao Saal in Lund University's new digital paper - "Mission is Possible".
"Lao Saal has a mission; to make it possible to – just by testing a blood sample – reveal, not only if you have cancer, but also which therapies may be most effective, and how well is the cancer actually responding to treatment. His idea is to trace the genetic material that escapes from tumours and into the blood circulation"
Please read more here
H.M. Konung Carl XVI Gustaf besöker CREATE Health
IVAs Kungl. Teknikresa besökte den 29 november CREATE Health Cancer Center på Medicon Village Science Park i Lund. Hedersdelegat vid besöket var H.M. Konung Carl XVI Gustaf. Landshövding Anneli Hulthén var en av delegaterna liksom IVAs VD Prof. Tuula Teeri. Delegationsledare för besöket var Kungl. Ingenjörsvetenskapsakademins Preses Leif Johansson.
Delegationen med H.M. Konung Carl XVI Gustaf i spetsen fick höra spännande föredrag om innovativ och världsledande forskning, presenterat av dagens värd Professor Carl Borrebaeck, CREATE Health, Lunds universitet. Delegationen fick även en presentation om Medicon Village och dess koncept av Mats Leifland och Mas Paulsson liksom företagspresentationer av några av de framstående bolagen på Medicon Village, SenzaGen, Alligator BioScience och SAGA Diagnostics. Besöket avslutades med en företagsvisning på Immunovia, fokuserat på cancerdiagnostik, innan sällskapet åt en avslutande lunch på Restaurant Inspira.
Lunds Fernströmpris till forskning om cancercellers samspel med omgivningen
Carl Borrebaeck tilldelas BiotechBuilders Award 2017
Carl Borrebaeck, Director för CREATE Health och Professor på Institutionen för Immuntekologi, Lunds Universitet, har tilldelats den prestigefyllda utmärkelsen BiotechBuilders Award för sin banbrytande forskning och framträdande roll som entreprenör inom Life science. Utmärkelsen delades ut i samband med BiotechBuilders årliga sammankomst, detta år med Hawaii tema, den 28 augusti.
Carl Borrebaeck tilldelades priset med motiveringen att han är en flerfaldigt framgångsrik entreprenör som bidragit till skapandet av en rad nya life science-företag, inklusive, bl.a. Alligator Bioscience, Immunovia, BioInvent och SenzaGen, Även hans ansträngningar för att bygga vetenskapliga nätverk, bland annat CREATE Health, Medicon Village, NOME (Nordic Mentor Network for Entrepreneurship) och Cancer Crosslinks konferensen, bidrar till hans position som en framstående ”bioteknikbyggare” och god representant för svensk life science.
Bakom de life science-företag som Professor Borrebaeck har grundat ligger många år av excellent forskning på avdelningen för Immunteknologi, LTH, Lunds Universitet. Professor Borrebaeck startade 2006 även det translationella cancer centret CREATE Health, LTH med syfte att på ett effektivare och bättre sätt ta forskningen ut till nytta för patienterna. Detta har varit mycket framgångsrikt och detta långsiktiga forskningsfokus som CREATE Health har är nu ett hett område som drar till sig stor uppmärksamhet världen över.
Tidigare vinnare av BB awards
Mathias Uhlén (2016)
Saeid Esmaeilzadeh & Ashkan Pouya (2015)
Gunilla Lundmark (2014)
Thomas Eldered (2013)
Johan Malmqvist (2012)
Hans Wigzell & Conny Bogentoft (2011)
Elisabeth Lindner (2010)
Torbjørn Bjerke (2009)
Om Biotech Builders
BiotechBuilders startades i Danmark, 2002, av Dr Jørgen Thorball en tidig morgon på Köpenhamns flygplats, Kastrup. Nyheter om en döende bioteknikindustri krävde åtgärder för att stimulera entreprenörer och ge nytt liv till branschen. Dr Torberg bjöd in ledande life science-företag för att initiera den första BiotechBuilders-träffen. I en lekfull och inspirerande miljö gavs de olika företagens grundare, visionärer, riskkapitalister och verkställande direktörer möjlighet att skapa nätverk och utbyta idéer. År 2009 testades evenemanget även till Sverige och har sedan dess hållits årligen i Stockholm, och det har varit en stor framgång och mycket uppskattat bland de deltagande.
The Scan-B study established in 2010, has now reached 10 000 patients. This makes is world’s largest genetically study of breast cancer. For more information please follow the link for a article in Swedish, or for more information please visit the Scan-B home page.
The registration for the 5th Cancer Crosslinks, is now open. This year’s sessions are;
Cancer and the Immune system
Personalized Healthcare – What is next?
with speakers from academia, industry, and health care.
The conference also enables plenty of networking opportunities.
Detailed information on program and registration can be found at:
Immonovia, spin out from CREATE health
The IMMray™ PanCan-d bloodtest, developed to discover pancreatic cancer through a blood test, was mentioned today in the Swedish News Swedish radio (SR) P1, and part of a longer radio broadcast (Vetandets värd), highlighting new discoveries in the field of pancreatic cancer.
The technology platform IMMray™ of Immunovia finds early biomarker signatures for several forms of cancer and autoimmune diseases, which gives it the potential to significantly increase the survival rate and quality of life of many patients.
Founded on the research of Professor Carl Borrebaeck at Lund University, Immunovia has developed a technology platform, IMMray™(Immunovia Antibody Microarray), for early diagnosis, prognosis and monitoring of cancers and autoimmune diseases.
”Complex diseases leaves footprints in the immune system. With a simple blood sample we can measure many proteins simultaneously in the immune response and thereby identify clinically relevant biomarker signatures for several forms of cancer, as well as autoimmune diseases like rheumatoid arthritis, Sjögren’s Syndrome, Lupus etc. that are hard to diagnose early,” says Mats Grahn, CEO of the molecular diagnostics company Immunovia.
The company’s first and main product is aimed for early diagnosis of pancreatic cancer.
For full article please follow the link.
Cancer Crosslinks 25 oktober 2017 SAVE THE DATE
Cancer Crosslinks 2017 will host a range of interesting topics presented by speakers from academia, industry, and health care, as well as plenty of networking opportunities.
The translational Cancer Faster Forward doctoral programme – CanFaster
The EU program 2020 MCSA COFUND has approved a unique doctoral program, CanFaster, focused on translational cancer research. CanFaster, will strengthen the cancer area at Lund university by enabling co-funding of 16 PhD students. In addition to research-specific courses the PhD students will be trained in entrepreneurship as well as get a better understanding of clinical practice and will be offered secondments within industry.
CanFaster build on collaboration between industry, healthcare and academia to strengthen and accelerate innovations and clinical implementation in oncology.
The ultimate goal is to increase patients' chance for a longer and healthier life through rapid implementation of new diagnostic and therapeutic solutions says Prof. Sara Ek, program director.
The program is hosted by CREATE Health and involves three faculties at Lund University. The fourteen researchers behind the application are: Thoas Fioretos, Lao Saal, Kristian Pietras, Lisa Rydén, Signe Borgquist, Kristina Drott, Mef Nilbert, Håkan Axelsson, Peter James, Yvonne Ceder, Sara Ek, Johan Axelsson, Inga-Lill Rahm Hallberg / Per Johansson and Malin Lindstedt.
"CanFaster is a valuable addition to CREATE Health and we are delighted to be able to further expand collaborations in Oncology at Lund University, nationally and internationally," says Carl Borrebaeck, Director of CREATE Health.
Fact: The program is run by CREATE Health Translational Cancer Center, and has been granted under the 2020 MCSA COFUND. The program, called “The translational cancer Faster Forward doctoral program – CanFaster”, is a joint venture between industry, healthcare and academia.
Prof. Carl Borrebaeck – Director of CREATE Health
Prof. Sara Ek – Programme Director
Prof. Kristian Pietras - Director of BioCARE.
Dr. Johanna Asklin - Innovation officer at LU Innovation.
Ms. Ebba Fåhreaus - CEO of SMILE.
Ms. Emma Roybon - Head of Research Administration at the Faculty of Medicine, Lund University.
MD/Prof. Mats Jerkeman - Represenative of Skåne University Hospital.
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Carl Borrebaeck, Director of CREATE Health in Nature Reviews Cancer online magazine.
This Opinion article, written by Professor Carl Borrebaeck, describes the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics. This is one of the research focuses with CREATE Health
Nyligen publicerades Cancer.se denna artikel om CREATE Health
CREATE Health är ett translationellt cancercentrum vid Lunds Universitet beläget på Medicon Village. Där möts specialister från Universitetsjukhuset och forskare från de vetenskapliga fakulteterna för arbeta mot samma mål, att bota cancer. Två viktiga aspekter för att nå det målet är tidig upptäckt och precisionsbehandling.
Save the date!
Make sure to book the 19 October 2016 in your calendar. Cancer Crosslinks is back in Lund!
Location: Medicon Village, Scheelevägen 2, Lund.
This is the successful conference linking Academia, Health care systems and Industry. Focus: Immunooncology and Perzonalized medicine.
For more information click here
Pancreatic Cancer Nordic Newsletter includes research from CREATE Health
Based on recent results from retrospective studies, that are now under publication, we can differentiate the early resectable stages of pancreatic cancer, stage I and II, from the healthy controls with 96% accuracy.
CREATE Health research cited in "Cancerfondsrapporten 2016
Vid CREATE Health samlas forskare från laboratorium och klinik för att studera biomarkörer och molekylära signaturer. De är bland annat på god väg att få fram nya tester för bättre diagnostik och behandling av cancer i bröst och bukspottkörtel.
Dagens Nyheter recently published an article about personalized medicine featuring interviews with leading scientists in personalized medicine, including Professor Carsten Rose from CREATE Health.
Today, the same medicines have different effect for two people having the same disease. Many drugs are expensive and if they do not provide a particularly good effect, they only cause a lot of suffering for the patient and an unnecessary cost for society.
Personalized Medicine means giving the right drug at the right dose at the right time to the right patient. It may sound simple, but since many processes interact in these diseases, the big picture is really complicated. However, since for example genetic analysis has become both cheaper and faster, the potential for tailoring the medicine has increased.
By measuring all genes and their activity in cells, we can get a fingerprint of the disease and that will help the doctors tailoring the right treatment.
- Instead of treating all patients in the same ways, we should only treat the patients having large chance for a good effect with a particular drug. In this case, the total price would be lower. In addition, it would be a great benefit for the patients, says Carsten Rose, professor in oncology at Lund University.
Photo credit: Superstock/Universal Group
Ny nationell standard för sjukvårdsintegrerad biobankning ökar förutsättningarna för individanpassad hälso- och sjukvård, Personalised Medicine. Vi står inför ett paradigmskifte. Cancerbehandling kommer att grundas på orsakerna till sjukdomen och varje patients förutsättningar. Sofia Waldemarson, Projektledare SWElife, Forskare CREATE Health Cancer Center, berättar här om de senaste nyheterna på området. Läs hela artikeln här
CREATE Health celebrates 10 years!
Taken together, the CREATE Health team has included seven research groups from three faculties, focusing on translational cancer research. Several important scientific findings have been made during these ten years, leading to publications in high-impact journals as well as patents. A number of research findings have also been commercialised and contributed to the founding of spin-off companies.
The 10-year anniversary will be highlighted in a dedicated Newsletter spring 2016!
Debate article on personalized medicine published in Dagens Nyheter
According to US estimates, 90 per cent of all drugs are effective in less than half of all patients. Therefore, both the US and EU are doing major investments in personalized medicine, while Sweden is currently falling behind. In the Swedish newspaper Dagens Nyheter, prominent researchers from five Swedish universities, including Professor Carl Borrebaeck from CREATE Health, emphasize the importance of similar investments in Sweden. The authors strongly urge financiers in Sweden to launch strategic research programs focusing on early and individualized drug therapies. The article was also highlighted in Dagens Medicin.
October is Breast cancer awareness month
Breast cancer mainly affects middle-aged and older women. The median age of onset is 64 years old. In total, more than 61,000 cancer diagnoses are made each year in Sweden. Of these, over 9000 are breast cancer diagnoses. This means that 20 women are diagnosed with breast cancer every day.
Earlier detection is vital to win the battle with all types of cancer. Lao Saal and his co-workers at CREATE Health show in their study that it is possible to detect metastases from breast cancer on average eleven months before they are detected with other methods, and in some cases 3 years before. They quantify circulating tumor DNA using a blood test to detect the metastatic disease. These results were highlighted on Swedish news channel TV4: http://tinyurl.com/saal-tv4-mp4
The study was funded by CREATE Health, Cancerfonden, Vetenskapsrådet, Gunnar Nilssons Cancerstiftelse, Gyllenstiernska Krapperupsstiftelsen and fru Berta Kamprads Stiftelse and others.
Successful Cancer Crosslinks day the 14th of October
The Cancer Crosslinks conference took place on 14th of October at Medicon Village, Lund University, and was a great success. It was fully booked and participants could enjoy initiated lectures from various research facilities, both from commercial laboratories and from university. The theme was personalized medicine and immuno-oncology and how we can facilitate that research will reach clinical application more quickly. During the day there were many opportunities for networking and collaborative discussions.
US Rogosin Institute invests in MAD for Cancer
MAD for Cancer website is official
Make A Difference for Cancer (MAD for Cancer), is collaborating with CREATE Health, and has now gone live with their website. To read more about the research and Principal Investigators involved in this multifocal cancer program at Lund University, go here.
Professor Carsten Peterson was awarded The Royal Academy of Arts and Sciences of Uppsala (Kungliga Vetenskapssamhället i Uppsala) prize for his interdisciplinary work.
The prize was parted at its annual ceremony in October 2014. He recieved the prize of 75.000 SEK for his “theteoretical physics based research that provides new knowledge about complex systems in molecular biology and medicine”. At the award ceremony Carsten held his laureate lecture "From stem cell to mature cell - a theoretical physicist´s perspective".
New movies about research within CREATE Health
Two new 3-minute movies about the work we do in CREATE Health has been produced in swedish by LTH and Lund University.
In "Fängslande forskning på LTH: Biomedicinsk teknik", Principal Investigator Thomas Laurell tells about lab-on-a-chip and the possibilities we get when we can diagnose cancer and even what treatment individual patients should get with this technique.
The other movie, "Fängslande forskning på LTH: Immunteknologi" revolves around Principal Investigator Sara Ek´s research and the technology developed to detect the aggressive cancer form called mantle cell lymphoma. A technology that is available for clinicians world-wide for better diagnostics.
Both movies can be found at Movies.
Carl Borrebaeck has been awarded the Royal Swedish Academy of Engineering Sciences, IVA, Gold Medal.
The justification is "his fundamental and pioneering research in applied immunology" and "his great entrepreneurship."
He will receive his medal on Friday, 28th of October at the Stockholm Concert Hall , from the Majesty King Carl XVI Gustaf during IVA’s 93rd Celebration Gathering.
Congratulations to Johan Malmström who will receive the very prestigious research grant of 1.5 million Euro from the European Research Council for the project where he uses advanced mass spectrometry to study the ability of Streptococcus pyogenes to cause infections.
Read more at
GPS - Global Proteome Survey
The CREATE Health PhD team has recently presented a new technique; Global Proteome Survey, in apublication in Molecular and Cellular Proteomics. In addition, the technique was high-lighted in an editorial in Nature Metods.
CREATE Health and Cancer
A short movie about CREATE Health and its main objectives.
Watch the movie here.
Miljonanslag till bättre behandling av bröstcancer
En fjärdedel av alla de 7000 kvinnor som årligen drabbas av bröstcancer riskerar metastaser, alltså återfall. De senaste åren har forskare vid Lunds universitet utvecklat en teknik som på förhand kan ta reda på vilka patienter som tillhör denna riskgrupp. Inom de närmaste två åren kommer metoden att börja testas av sjukvården i Lund och Malmö.